## AAPG: Ascentage Pharma Group Internat - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -0.2% below STRENGTH zone (4.0-10.0%); PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: declining volume (52% of avg).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($30.36)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA**
- Source: WRIC ABC 8News | 20251205T052125 | Bullish | Relevance: 100%
- Ascentage Pharma has received clearance from the US FDA and EMA to begin a global registrational Phase III study (POLARIS-1) for olverembatinib, combined with chemotherapy, as a first-line treatment for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Preliminary data from the upcoming ASH 2025 Annual Meeting abstract showed promising efficacy and a favorable safety profile for patients combining olverembatinib with low-intensity chemotherapy. This marks a significant progression in addressing the high unmet medical needs for Ph+ ALL patients globally.

**2. Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA**
- Source: GlobeNewswire | 20251204T190000 | Bullish | Relevance: 100%
- Ascentage Pharma has received clearance from the US FDA and EMA for a global registrational Phase III study (POLARIS-1) of olverembatinib in combination with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The study is simultaneously enrolling patients globally to accelerate olverembatinibâ€™s path to registration, with initial data showing promising MRD negativity rates and favorable safety. This marks a significant step in addressing unmet clinical needs in Ph+ ALL, building on olverembatinib's prior approvals in China for CML.

**3. Ascentage Pharma (NASDAQ: AAPG) reports 65% MRD in Ph+ ALL as FDA, EMA clear Phase III**
- Source: Stock Titan | 20251205T052125 | Bullish | Relevance: 100%
- Ascentage Pharma (NASDAQ: AAPG) has received clearances from the US FDA and EMA for a global registrational Phase III study (POLARIS-1) of olverembatinib combined with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The study has already begun in China and is enrolling patients globally to accelerate regulatory approval in the US and Europe. Early data presented at ASH 2025 indicated a 65% MRD-negativity and molecular MRD-negative complete response rate after three treatment cycles, alongside a favorable safety profile.

**4. Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA**
- Source: Yahoo Finance | 20251205T000922 | Bullish | Relevance: 100%
- Ascentage Pharma has received clearance from the US FDA and EMA for a global registrational Phase III study (POLARIS-1) of olverembatinib in combination with chemotherapy for newly diagnosed patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). This marks the second global Phase III study for olverembatinib cleared by regulators in these regions, with POLARIS-1 also initiated in China. Early data from the study, to be presented at ASH 2025, shows promising efficacy and a favorable safety profile for olverembatinib in this patient population.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-04 | Oppenheimer | $45 | $0 | 0% |
| 2025-11-24 | Truist Securiti | $51 | $0 | 0% |
| 2025-11-10 | BTIG | $50 | $0 | 0% |
| 2025-11-05 | Piper Sandler | $48 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-04 | Oppenheimer | init | Outperform |
| 2025-11-24 | Truist Securiti | init | Buy |
| 2025-11-10 | BTIG | init | Buy |
| 2025-11-05 | Piper Sandler | init | Overweight |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 0.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- UBS Group AG: 0.0% (+149.4%)
- XY Capital Ltd: 0.0% (+224.1%)
- Point72 (DIFC) Ltd: 0.0% (-14.2%)
- Tema Etfs LLC       : 0.0% (-33.0%)
- ABC Arbitrage SA: 0.0% (+100.0%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

Revenue growth strong at 227% YoY. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $2.6B |
| Beta | 1.11 |
| 52W Range | $16.50 - $48.45 |
| Short Interest | 0.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | N/A |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 improving modestly (+0.9% over 5 days). Below STRENGTH zone by 4.2pp (needs >4.0% for momentum thesis). MRS_5 turning positive (2.9%) - potential reversal signal. RSI neutral at 50. Volume at 52% of 20MA suggests lack of conviction. OFD pattern: +MTL (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.19% (CS: 52) | Neutral |
| RSI_14 | 50.5 | Neutral |
| MACD Histogram | 0.14 | Bullish |
| vs SMA20 | 1.021x | Above |
| vs SMA50 | 0.955x | Below |
| vs SMA200 | 1.034x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $32.88
- **Stop Loss:** $30.36 (7.7% risk)
- **Target:** $35.40 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 198
- **Position Value:** $6,510.24
- **Portfolio %:** 6.51%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with balanced risk appetite. VIX near 15th percentile of 52-week range signals calm conditions, while modest yield curve steepening (54bps 10Y-3M) suggests healthy growth expectations. Breadth at 52% indicates selective participation rather than broad-based momentum.*

### Earnings

**Next:** 2026-03-26 (Est: $0.00)

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*